CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisi...
Phase 1, Phase 2
Detroit, Michigan, United States of America and 12 other locations
This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enroll...
Phase 3
Royal Oak, Michigan, United States and 107 other locations
The objective of this study is to determine the maximum safe dose of Ra-223 in combination with fractionated (split doses) docetaxel when given to su...
Phase 1
Detroit, Michigan, United States and 3 other locations
Prostate cancer is usually treated by reducing the amount of testosterone in the body. PRL-02 depot is a potential treatment for me ...
Phase 1
Toledo, Ohio, United States and 13 other locations
Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate...
Phase 1
Detroit, Michigan, United States and 16 other locations
The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate...
Phase 4
Detroit, Michigan, United States and 9 other locations
This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also de...
Ann Arbor, Michigan, United States and 7 other locations
A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate...
Phase 1, Phase 2
Detroit, Michigan, United States and 22 other locations
This is a phase 1 study to assess the safety and tolerability of ARX517 in adult subjects with Metastatic Castration-Resistant Prostate Cancer...
Phase 1
Ann Arbor, Michigan, United States and 8 other locations
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic the...
Phase 1, Phase 2
Detroit, Michigan, United States and 53 other locations
Clinical trials
Research sites
Resources
Legal